Synektik S.A. stock (PLSYNEK00016): imaging specialist reports solid quarterly growth

Polish medical imaging group Synektik S.A. has reported higher revenue and EBITDA in its latest quarterly update, reflecting continued demand for diagnostic equipment and radiopharmaceuticals across Central Europe.

Polish healthcare technology company Synektik S.A. has reported year?on?year revenue and earnings growth in its most recent published quarterly results, highlighting resilient demand for medical imaging systems and radiopharmaceuticals in its core markets, according to the company’s investor materials and recent reports on its website as of 03/2025Synektik investor information as of 03/2025.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Synektik
• Sector/industry: Medical technology and imaging
• Headquarters/country: Poland
• Core markets: Central and Eastern European healthcare providers
• Key revenue drivers: Diagnostic imaging equipment and radiopharmaceuticals
• Home exchange/listing venue: Warsaw Stock Exchange (ticker if verified)
• Trading currency: Polish zloty (PLN)

Synektik S.A.: core business model

Synektik S.A. focuses on supplying hospitals and diagnostic centers with advanced medical imaging solutions, including systems used in cardiology, oncology and neurology. The group’s operations combine equipment distribution with related services, software and radiopharmaceutical production for nuclear medicine.

The company is active across the value chain from project design for imaging suites to installation, maintenance and upgrade services. This integrated approach is designed to build long?term customer relationships and recurring service revenue alongside one?off equipment sales, according to the company’s corporate description as of 2024Synektik corporate profile as of 2024.

In addition to distribution partnerships with global technology manufacturers, Synektik has built its own competencies in radiopharmaceuticals used in positron emission tomography (PET) and other nuclear imaging techniques. This combination of third?party devices and proprietary products differentiates the business among regional medical technology providers.

Main revenue and product drivers for Synektik S.A.

Synektik’s revenue base is largely tied to the investment cycles of hospitals and diagnostic centers, which procure imaging systems such as PET/CT scanners, MRI devices and related software platforms. Sales in this segment typically fluctuate with public and private healthcare spending programs across Poland and neighboring countries.

A second key driver is the production and sale of radiopharmaceuticals, particularly tracers used in PET diagnostics for oncology and cardiology. These products require specialized facilities and strict regulatory compliance, creating higher barriers to entry and supporting margin potential relative to pure hardware distribution, according to the firm’s investor presentations as of 2024Synektik presentations as of 2024.

Service and maintenance contracts, along with software and application support, contribute an additional recurring stream of income. This activity can smooth revenue between large hardware tenders, and it often expands as the installed base of imaging systems grows across the region’s healthcare providers.

Conclusion

Synektik S.A. offers investors exposure to Central European healthcare investment, with a focus on diagnostic imaging technology and radiopharmaceuticals. The latest reported quarterly figures indicate ongoing revenue and earnings growth, while the company’s mix of equipment, consumables and services provides a diversified business model. For US investors following international medtech names, the stock illustrates how regional specialists in imaging and nuclear medicine can participate in long?term trends such as cancer diagnostics and aging populations, while still being influenced by local healthcare budgets and regulatory frameworks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.